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Abstract
Feline immunodeficiency virus (FIV) targets helper T cells by attachment of the envelope
glycoprotein (Env) to CD134, a subsequent interaction with CXCR4 then facilitating the process
of viral entry. As the CXCR4 binding site is not exposed until CD134-binding has occurred then
the virus is protected from neutralising antibodies targeting the CXCR4-binding site on Env.
Prototypic FIV vaccines based on the FL4 strain of FIV contain a cell culture-adapted strain of FIV
Petaluma, a CD134-independent strain of FIV that interacts directly with CXCR4. In addition to a
characteristic increase in charge in the V3 loop homologue of FIVFL4, we identified two mutations
in potential sites for N-linked glycosylation in the region of FIV Env analogous to the V1–V2 region
of HIV and SIV Env, T271I and N342Y. When these mutations were introduced into the primary
GL8 and CPG41 strains of FIV, the T271I mutation was found to alter the nature of the virus-
CD134 interaction; primary viruses carrying the T271I mutation no longer required determinants
in cysteine-rich domain (CRD) 2 of CD134 for viral entry. The T271I mutation did not confer
CD134-independent infection upon GL8 or CPG41, nor did it increase the affinity of the CXCR4
interaction, suggesting that the principal effect was targeted at reducing the complexity of the Env-
CD134 interaction.
Background
The initial event in the process of viral entry is the interac-
tion between the virus and its cellular receptor. For HIV-1,
the trimeric Env complex comprising gp120 and gp41
attaches to the primary viral receptor CD4 [1,2] on the
surface of the target cell. This interaction is believed to
induce a conformational change in gp120 that leads to
exposure of the binding site for the coreceptor, usually the
chemokine receptors CXCR4 and CCR5 [3,4]. Engage-
ment of the coreceptor triggers a further conformational
change in the Env complex that results in exposure of the
gp41 fusion domain and initiates the process of fusion of
the viral and cellular membranes. Given that the virus-
receptor interaction initiates the process of viral entry, the
binding sites on gp120 for the primary and co-receptors
should, logically, make good targets for neutralising anti-
bodies. Indeed, the monoclonal antibody (MAb) b12 [5]
targets the CD4 binding site on gp120 and has broad neu-
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MAbs such as 17b, target the chemokine receptor binding
site, engaging the Env complex post-attachment to CD4 (a
"CD4-induced" epitope). During natural infection anti-
bodies targeting the CD4 binding site are seldom elicited
[6]; the CD4 binding site is recessed in gp120, partially
occluded by the hypervariable loops and protected by
"conformational masking" [7-9]. When such antibodies
are elicited, they display potent, broad neutralizing activ-
ity [6]. In contrast, although the co-receptor binding site
is not exposed on the virion until after CD4 binding has
occurred, antibodies targeting the co-receptor binding site
are common in sera from HIV-infected patients, and in
the presence of soluble CD4 display potent cross-clade
neutralising activity [10].
Some strains of HIV and SIV are capable of by-passing the
primary receptor and interacting directly with the co-
receptor [11-15]. In these "CD4-independent" strains of
virus, the chemokine receptor binding site may be more
exposed [16] and as such, they may be more sensitive to
neutralising antibodies than their CD4-dependent coun-
terparts [11,16-19]. Accordingly, the humoral immune
response may exert a strong selective pressure against the
emergence of CD4-independence in vivo: CD4-independ-
ent strains would have a broader cell tropism in vivo,
assisting with viral dissemination into cellular compart-
ments where CD4 expression may be low, for example the
CNS [20-22]. The inextricable link between receptor
usage, cell tropism and neutralisation sensitivity [23,24]
may advise the design of novel immunogens for HIV vac-
cination. Deletion of the V2 hypervariable loop from HIV-
1 SF162 renders the virus susceptible to virus neutralisa-
tion [25]. Antibodies raised against the SF162ΔV2 immu-
nogen target the CD4-binding site preferentially
suggesting that the V2 loop deletion exposes the CD4-
binding site. The V2-loop deletion in SF162ΔV2 elimi-
nates a site for N-linked glycosylation and studies with
HIV-1 ADA have shown that loss of a single N-linked gly-
can from HIV-1 ADA gp120 switches the virus from a
CD4-dependent to CD4-independent phenotype [12] by
re-positioning the V1/V2 loops. Similarly, mutation of
glycosylation sites in SIVmac239 Env enhance CD4-inde-
pendent infection mediated by CCR5 [26]. Taken
together, these data indicate it may be possible to manip-
ulate the humoral immune response towards the CD4
binding site by modulating the surrounding environment
on gp120 and in doing so, create an immunogen that will
induce broadly neutralising antibodies.
Feline immunodeficiency virus (FIV) is a widespread
pathogen of the domestic cat and in its natural host spe-
cies it induces a disease state similar to AIDS in human
beings. FIV targets CD4+ helper T cells by binding to
CD134 (also known as OX40) [27], a member of the
tumour necrosis factor receptor superfamily that is
expressed selectively upon feline helper T cells [28,29]. All
primary strains of FIV tested to date, utilise CD134 as a
receptor for viral entry [27,29,30], however cell culture-
adapted strains of FIV such as Petaluma F14 and 34TF10
[31,32] are able to infect and form syncytia in cell lines in
the absence of CD134 [27]. CD134-independent FIV
infection is mediated by a direct interaction with CXCR4
[33,34], analogous to infection with CD4-independent
strains of HIV [13]. However, over-expression of CXCR4
alone is sufficient to render cells susceptible to infection
with some strains of FIV [35], suggesting that such strains
of virus may have a propensity to adaptation in cell cul-
ture to CD134-independence.
Whole inactivated virus vaccines derived from the FL4 cell
line (a cell line infected persistently with the Petaluma
strain of FIV [36]) induce both humoral and cellular
immunity and offer a degree of protection against chal-
lenge with heterologous strains of virus [37-42]. Accord-
ingly, the FL4 cell line has provided the basis for the first
commercially available FIV vaccine (Fel-O-Vax FIV, Fort
Dodge), approved for use in the USA, Japan, New Zealand
and Australia. The vaccine has attracted a degree of contro-
versy as independent experiments have failed to demon-
strate protective efficacy against heterologous challenge
[43], addressing these conflicting reports is of importance
to advancing lentiviral vaccine development [44]. Previ-
ously, Env-based immunogens derived from primary
strains of FIV failed to induce protective immunity, and in
some cases led to an accelerated viraemia following chal-
lenge [45-51]. In order to inform the design of lentiviral
vaccines that will induce broadly neutralising antibodies,
we examined the FL4 virus for the presence of novel fea-
tures acquired during the process of adaptation to cell cul-
ture that may have contributed to its enhanced
immunogenicity. Here, we identify a potential site for N-
linked glycosylation that is highly conserved among field
isolates of FIV but which is absent from the FL4 Env. By
introducing similar mutations into primary isolates of
FIV, we demonstrate that N-linked glycosylation at this
site impacts on the virus-receptor interaction. These find-
ings bear striking similarities to observations with both
HIV and SIV [52,53,53-57] and may provide an insight
into the mechanism by which the FL4 immunogen
induces virus neutralising antibodies.
Methods
DNA constructs and mutagenesis
The FL4 strain of FIV lacks sites for N-linked glycosylation
at Asn-269 due to a threonine to isoleucine switch at 271
(T271I), and Asn-342 due to an asparagine to tyrosine
substitution at 342 (N342Y). We mutated these sites in
the GL8 and CPG41 Envs by amplification using a 5'
primer from the leader-SU junction 5-TAGACGCGTAA-Page 2 of 16
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TATTATAACAGATGTTATTAGCACAT-3' (ENV 7076) or 5'
GGTCTTGAATCTGTGAAGTGTACCACATA (ENV 7288).
The amplification products were purified by agarose gel
electrophoresis (QIAEx gel extraction kit, QIAGen, UK)
and used as 5' primer in conjunction with a 3' primer from
the RRE region 5'-AATGGATTCATATGACACATCTTCCT-
CAAAGGG (3' NDE) to amplify the full-length SU-TM
products. The mutated Envs were sub-cloned into the
GL8MYA molecular clone as Mlu-I/Nde-I fragments as pre-
vious [58]. The double mutant (Asn-269 and Asn-342)
was generated by amplification firstly using 5'MLU and
ENV-7076, extending using ENV-7288 and then finally
amplifying the entire Env using the double-mutated frag-
ment and 3'NDE primer. The sequences of each construct
were confirmed using a BigDye® Terminator v1.1 cycle
sequencing kit (Applied Biosystems) followed by analysis
on an Applied Biosystems 3700 genetic analyser.
Cells and viruses
MYA-1 [59] cells and MCC [60]-derived cell lines were
cultured in RPMI 1640 medium. 293T were maintained in
Dulbeccos modification of Eagle's medium (DMEM). All
media were supplemented with 10% foetal bovine serum
(FBS), 2 mM glutamine, 0.11 mg/ml sodium pyruvate 100
IU/ml penicillin, 100 μg/ml streptomycin. The medium
for MYA-1 cells was supplemented with conditioned
medium from a murine cell line (L2.3) transfected with a
human IL-2 expression construct (kind gift of M. Hattori,
University of Tokyo) at a final concentration equivalent to
100 U/ml of recombinant human interleukin-2 (IL-2),
and 50 μM 2-mercaptoethanol. All media and supple-
ments were obtained from InVitrogen Life Technologies
Ltd. (Paisley, UK). Cell lines expressing CD134 and the
chimaeric constructs were maintained in G418 (InVitro-
gen, Paisley, UK).
Molecular clones carrying the Asn-269 (T271I), Asn-342
(N342Y) or the Asn-269/Asn-342 double mutant (Δ2N)
were transfected into 293T cells using Superfect (QIAGen)
and recovered by co-culture with MYA-1 cells at 72 hrs
post-transfection. Viruses were expanded in MYA-1 cells
before harvesting, 0.45 μm filtration and storage at -80°C.
Polyacrylamide gel electrophoresis (PAGE) analyses
1.0 to 1.5 × 107 infected MYA-1 cells were washed by cen-
trifugation (1000 rpm, 5 mins.) through ice-cold phos-
phate buffered saline and resuspended in lysis buffer
comprising 1% CHAPS in 10 mM Tris (ph 7.4), 150 mM
sodium chloride, 2 mM ethylenediamine tetraacetic acid
and supplemented with a Complete™ protease inhibitor
tablet (Roche Applied Science, Burgess Hill, UK). Lysates
were mixed with reducing Laemmli sample buffer [61]
and separated on either 4–15% polyacrylamide gels
(Ready-Gel, Biorad, Hemel Hempstead, UK) or 10% poly-
acrylamide gels (prepared as previously [62]). Separated
proteins were transferred to nitrocellulose by electroblot-
ting (iBlot™, Invitrogen); viral antigens were detected
using pooled polyclonal cat serum from FIV infected cats
followed by biotinylated goat anti-cat IgG, or monoclonal
antibody vpg71.2 followed by biotinylated goat anti-
mouse IgG conjugates (Vector Laboratories Ltd., Peterbor-
ough, UK). Bound conjugate was revealed using the
Vectastain ABC kit and 5-bromo-4-chloro-3-indolyl phos-
phate/nitroblue tetrazolium substrate (Vector Laborato-
ries Ltd.).
Preparation of HIV (FIV) pseudotypes
FIV env gene expression constructs GL8, B2542, CPG41
and PPR have been described previously [27,30,63]. 5 μg
of each VR1012-env and 7.5 μg of pNL4-3-Luc-E-R- were
co-transfected into HEK-293T cells using SuperFect acti-
vated dendrimer (QIAgen) as per manufacturer's instruc-
tions. The nomenclature "HIV(FIV)" denotes an FIV Env
protein on an HIV particle. Culture supernatants were col-
lected at 48 hours post-transfection, filtered at 0.45 μm
and frozen at -80°C until required. Target cell lines were
seeded at 5 × 104 cells per well of a CulturPlate™-96 assay
plate (Perkin Elmer, Life and Analytical Sciences, Beacons-
field, UK) and used immediately. The cells were then
infected with 50 μl of HIV (FIV) luciferase pseudotypes,
cultured for 72 hours and then luciferase activity quanti-
fied by the addition of 50 μl of Steadylite HTS™ (Perkin
Elmer) luciferase substrate prior to measurement by single
photon counting on a MicroBeta TriLux luminometer
(Perkin Elmer).
Virus neutralisation assays
Sera were diluted 5-fold in MYA-1 culture medium and
then 25 μl of each dilution (in triplicate) was incubated
with 25 μl of HIV(FIV) luciferase pseudotype, incubated
for one hour at 37°C and then added to 50 μl (5 × 104
cells) of CLL-CD134 cells per well of a CulturPlate™-96
assay plate (Perkin Elmer, Life and Analytical Sciences,
Beaconsfield, UK). The cells were then cultured for 72
hours and luciferase activity quantified by the addition of
100 μl of Steadylite HTS™ (Perkin Elmer) luciferase sub-
strate and measurement by single photon counting on a
MicroBeta luminometer (Perkin Elmer).
Growth of FIV in vitro
The growth of FIV in vitro was assessed in MYA-1 cells.
Supernatants were collected every three days and assayed
for reverse transcriptase (RT) activity using Lenti-RT non-
isotopic RT assay kit (Cavidi Tech., Uppsala, Sweden). RT
values were then calculated relative to purified HIV-1 RT
standard.
Syncytium formation in adherent cells
AH927 cells stably transduced with pDONAI vector only,
or with vector encoding fCD134, fCRD1xhCD134 or
hCD134, were transfected with each env construct usingPage 3 of 16
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hours at 37°C. The cells were then fixed and stained with
1% methylene blue/0.2% basic fuchsin in methanol and
photographed using a Leica DMLB microscope (Leica
Microsystems (UK) Ltd., Milton Keynes) and Photomet-
rics SenSys digital camera (Photometrics Ltd., Tucson,
USA).
Inhibition of viral entry
1 × 105 MYA-1 or CLL-CD134 cells were incubated with
the CXCR4 antagonist AMD3100 [64-66] in complete
medium in 96-well culture-treated luciferase assay plates
(CulturPlate™ 96) for 30 minutes at 37°C. Viral pseudo-
types were then added and the plate returned to the 37°C
incubator. Cultures were maintained for 72 hours post-
infection at which point 100 μl of Steadylite HTS™ (Perkin
Elmer) luciferase substrate were added and luminescence
measured by single photon counting on a MicroBeta
luminometer (Perkin Elmer).
Production of recombinant IgG-Fc fusion proteins
FIV Env SU-Fc fusion proteins were produced by amplify-
ing the SU coding sequence with the oligonucleotide
primers 5'-CGATCTAGAAACAATAATTATGGCAGAAG-3'
and 5'-GGCGGCCGCTGGTACCAC(C/T)AAGTAATC-3'
corresponding to the start codon for Env leader sequence
and the SU/TM junction respectively. The amplified prod-
ucts were cloned as XbaI/NotI fragments into pTorsten
[67], expressed in CHO cells in CELLine AD1000 bioreac-
tor flasks (Integra Biosciences (Scientific Laboratory Sup-
plies, Nottingham, U.K.)) in medium supplemented with
low IgG serum (Integra Biosciences). Culture supernatant
was filtered at 0.22 μm and frozen at -80°C prior to use in
order to preserve optimal bioactivity. Proteins were puri-
fied from culture supernatant as previous [28].
Results
Characterisation of FIV FL4 SU
The FL4 cell line is a feline lymphoblastoid cell line that is
persistently infected with the Petaluma strain of FIV [68].
The virus derived from FL4 cells provided the substrate for
whole inactivated virus vaccines that conferred strain-spe-
cific immunity to infection with FIV [37,38,41], and, in
combination with the subtype D Shizuoka strain, the
basis for Fel-O-Vax FIV (Fort Dodge Animal Health). The
predicted amino acid sequence of the FL4 vaccine strain
was compared with that of the prototypic F14 and 34TF10
clones of the Petaluma isolate of FIV [31,69] in order to
identify non-synonymous mutations in gp120 that may
have been acquired during the process of cell culture
adaptation. Unique amino acid substitutions in SU were
identified at T271I, N342Y, W347R and F388L (amino
acid numbering is relative to F14 [31]). Of these substitu-
tions, T271I and N342Y ablated potential sites for N-
linked glycosylation in SU. We asked whether the T271I,
N342Y substitutions were observed in field isolates by
comparing the FL4 sequence with published sequences
using the BLAST search program [70]. The potential site
for N-linked glycosylation targeted by the N342Y muta-
tion was unique to FL4 (in comparison with 35 published
amino acid sequences) while the N-linked glycosylation
site targeted by the T271I mutation was absent in only
three other sequences (n = 34); Aomori 1 and 2 [71] (two
related Japanese isolates) and FC2 [72]. Given that the
T271I and N342Y substitutions were uncommon
amongst field isolates and present in neither the F14 and
34TF10 molecular clones, nor the parent biological isolate
of FIV Petaluma (not shown), we hypothesised that these
mutations may have either been acquired during the proc-
ess of cell culture adaptation, or amplified from an initial
quasispecies during cell culture. Similar adaptations have
been shown previously to affect receptor usage for lentivi-
ruses and to alter neutralisation sensitivity and immuno-
genicity [25,52,73].
We next examined the predicted locations of T271I and
N342Y substitutions on the FIV SU protein, comparing
the locations with schematic structural models for FIV SU
and HIV SU based on predictive algorithms for secondary
structure [74], disulphide bond architecture [75,75,76]
and informed by the solved crystal structure of HIV Env
[7,8]. T271I and N342Y are predicted to lie in a region of
FIV SU which may be analogous to the area at the base of
the HIV V1 and V2 stem (Fig. 1A). For the purpose of this
study, and to assist with direct comparisons between FIV
and HIV, this region is referred to as the V1/V2 homo-
logue herein. Although this region of FIV Env was thought
formerly to be relatively conserved, a reappraisal based on
accumulated Env sequence data indicates pockets of vari-
ability within this region, as illustrated when variability is
plotted using consensus position-specific scoring matrix
analysis [77] (PSSM, Fig. 1B). Mutations in the V1/V2
region of HIV SU affect the interaction between the HIV
SU and its receptor and co-receptor(s) and alter the anti-
genicity of the envelope glycoprotein, promoting the pro-
duction of antibodies targeting the CD4 binding site
[12,73,78,79]. Similarly, for HIV loss of N-linked glycans
from this region contribute to CD4-independence [12].
Incorporation of the T271I and N342Y mutations into 
primary isolates of FIV
The T271I and N342Y mutations were reproduced in
molecular clones of FIV GL8 and a chimeric molecular
clone bearing the CPG41 Env in the GL8 backbone by
site-directed mutagenesis. Constructs were transfected
into 293T cells and replication competent virus was recov-
ered into IL2-dependent feline T cells (MYA-1). All viruses
replicated with similar efficiency in MYA-1 cells (not
shown). Bulk supernatants were prepared, virus pelleted
by ultracentrifugation and analysed by SDS-PAGE. Immu-Page 4 of 16
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A. Schematic structural model of the FIV SU proteins illustrating the locations of the T271I and N342Y mutations (red), con-served cys eine residues (green) and predicted sit s for N-linked glyc sylation ()Figur  1
A. Schematic structural model of the FIV SU proteins illustrating the locations of the T271I and N342Y mutations (red), con-
served cysteine residues (green) and predicted sites for N-linked glycosylation (). Residues in the V1/V2 or V3 homologues dis-
playing >10% variation from the consensus sequence are shaded. B. Position-specific scoring matrix (PSSM) analysis of amino 
acids 248 to 445 of FIV SU encompassing the homologous regions to HIV V1/V2 and V3 illustrating the likelihood of the con-
sensus amino acid appearing in an SU sequence. T271 and N342 are arrowed.
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Retrovirology 2008, 5:77 http://www.retrovirology.com/content/5/1/77noblotting using polyclonal anti-FIV (Fig. 2A) confirmed
that similar levels of viral proteins were produced by each
virus. Although a marginal reduction in the apparent size
of Env was suggested in the Δ2N mutants of both GL8 and
CPG41 (Fig. 2A), this was visualised more readily when
the GL8 viruses were separated on a 10–20% gradient gel
(Fig. 2B) and probed with the subtype-specific mono-
clonal antibody vpg71.2 (vpg71.2 does not recognise
CPG41 Env). Under these conditions, a clear downward
shift could be discerned in the Δ2N double mutant virus
but in neither of the single mutants.
Effect of the T271I and N342Y mutations on receptor 
usage by GL8 and CPG41
FIV GL8 and CPG41 require determinants in both CRDs 1
and 2 of CD134 for viral entry while infection with strains
such as PPR and B2542 is mediated by CRD1 alone
[30,63]. Accordingly, a chimeric CD134 molecule com-
prising CRD1 of feline CRD1 in the context of human
CD134 may be used to differentiate strains such as GL8
and CPG41 from strains such as PPR and B2542 in viral
entry assays (reviewed in [80]). The feline cell lines
AH927-FX4P [81] (Fig. 3A) and MCC [27] (Fig. 3B) stably
expressing full-length feline CD134 (CD134) or a chi-
meric receptor bearing feline CD134 CRD1 in the context
of human CD134 (CRD1), or transduced with vector only
(CON) were infected with HIV (FIV) luciferase pseudo-
types bearing the wild type (WT), T271I, N342Y or Δ2N
Envs derived from GL8 and CPG41 and viral entry was
assessed. Pseudotypes bearing either the WT or mutant
Envs infected AH927-FX4P (Fig. 3A.) and MCC (Fig. 3B.)
cells expressing CD134 with comparable efficiency. Infec-
tion of CRD1-expressing cells was diminished greatly for
both GL8 and CPG41 WT Envs, consistent with previous
data [30,63]. The N342Y mutants behaved ostensibly the
same as the WT Envs, demonstrating a marked preference
for CD134 over the CRD1 chimera. In contrast, introduc-
tion of the T271I and Δ2N Envs partially restored the abil-
ity of the viruses to use the CRD1 chimera (significant
enhancement, t-test). The effect was most stark on MCC
cells (Fig. 3B.) where GL8 WT infection of MCC-CRD1
was 300-fold less efficient, whereas infection with the
T271I and Δ2N mutants was reduced by only 27 and 47-
fold respectively, suggesting that the presence of the T271I
mutation, but not the N342Y mutation, facilitated the
interaction between the GL8 Env and CRD1 of CD134.
If the T271I mutation conferred enhanced usage of the
CRD1 chimera as a receptor then we would predict that
direct transfection of the T271I mutant into AH927-FX4P
cells expressing the CRD1 chimera would result in
enhanced syncytium formation compared to the wild
type. We therefore compared the ability of the GL8 and
CPG41 WT, T271I, N342Y and Δ2N Envs to induce syncy-
Mutant proviral clones bearing T271I or N342Y yield infectious virusFigure 2
Mutant proviral clones bearing T271I or N342Y yield infectious virus. A. Pelleted virus from MYA-1 cells infected with GL8 (1–
4) and CPG41 (5–8) viruses bearing WT (1,5), T271I (2,6), N342Y (3,7) or Δ2N (4,8) were separated by reducing SDS-PAGE 
on a 12% acrylamide gel, transferred to nitrocellulose and probed with pooled cat anti-FIV. Approx. molecular mass (kDa) are 
on left, primary reactivities Env, prGag and CA arrowed on right. B. 10–20% gradient gel analysis of GL8 WT (1), T271 (2), 
N342Y (3) and Δ2N (4) probed with anti-FIV (subtype-specific) SU monoclonal antibody vpg71.2. Approx. molecular mass 
(kDa) on left, Env is arrowed on right.
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Infection of the feline cell lines AH927-FX4P [81] (A) and MCC [27] (B) stably-transduced with retroviral vectors encoding full-length fCD134 (CD134), CRD1 of fCD13  in the context of hCD134 (CRD1) or vector only control (CON)Figure 3
Infection of the feline cell lines AH927-FX4P [81] (A) and MCC [27] (B) stably-transduced with retroviral vectors encoding full-
length fCD134 (CD134), CRD1 of fCD134 in the context of hCD134 (CRD1) or vector only control (CON). Infection of both 
cell lines expressing CRD1 was enhanced significantly in the T271I and Δ2N Envs. Histograms display the mean +/-SE (n = 3), 
arrows show P-values, t-test. C.) Syncytium formation in AH927-FX4P cells expressing feline CD134 (CD134), or feline 
CD134 CRD1/human CD134 chimera (CRD1). Cells were transfected with eukaryotic expression vectors bearing the GL8 or 
CPG41 envs carrying the WT, T271I, N342Y or Δ2N sequences. Cells were fixed and stained at 48 hours post-transfection, 
representative fields are shown.
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Retrovirology 2008, 5:77 http://www.retrovirology.com/content/5/1/77tium formation in AH927 cells expressing CD134, the
CRD1 chimera or vector only. Introduction of the T271I
mutation enhanced syncytia formation in both CD134
and CRD1 chimera expressing cells (Fig. 3C). Few syncytia
were observed in the CRD1 chimera-expressing cells trans-
fected with GL8 or CPG41 WT Envs. The N342Y Envs
induced fewer, and smaller syncytia in CD134-expressing
cells than the WT Envs and few syncytia in the CRD1-
expressing cells. Surprisingly, while HIV (FIV) pseudo-
types bearing the GL8 and CPG41 Δ2N Envs behaved
essentially the same as the pseudotypes bearing the T271I
mutant Envs in the entry assay (Fig. 3A and 3B), in the
syncytial assay, the Δ2N mutant Envs showed a marked
reduction in syncytia formation compared with the T271I
mutants. Similar results were observed with both the GL8
and CPG41 series of Envs indicating that in the presence
of the N342Y mutation the enhancement of syncytium
formation conferred by T271I was lessened. Neither the
wild type nor the mutant Envs induced syncytium forma-
tion in the vector-only control cells (not shown). The data
suggest that the potential N-linked glycosylation sites at
positions 269 (NNT) and 342 (NTS) impact on the inter-
action between the viral Env and its receptor(s).
Effect of glycosylation site ablation on sensitivity to 
CXCR4 antagonist
The enhanced usage of the CD134-CRD1 chimaera by the
T271 mutants may have arisen due to a less stringent
interaction between FIV Env and CD134, the N-linked
glycosylation site at 269 contributing to the receptor bind-
ing surface. Alternatively, removal of the N-linked glyco-
sylation may have enhanced the ability of the Env to
interact with CXCR4, either facilitating partial CD134-
independent entry or by enhancing the affinity for
CXCR4. To address the latter possibility, we examined the
sensitivity of viral pseudotypes bearing the WT, T271I or
N342Y Envs to the CXCR4 antagonist AMD3100 (Fig. 4).
Sensitivity to AMD3100 was assessed on MYA-1 T cells
(expressing low levels of CXCR4 [82]) and CLL-CD134
(expressing high levels of CXCR4 (Willett et al., unpub-
lished data). Where CXCR4 was limiting (MYA-1 cells),
infection with both GL8 and CPG41 was inhibited effi-
ciently by AMD3100. Neither the T271 nor the N342Y
mutation enhanced or reduced sensitivity to AMD3100
although it was notable that GL8 was significantly more
sensitive to antagonism by AMD3100 than CPG41 (at 0.1
μg/ml AMD3100 there was a 100-fold reduction in GL8
entry compared with 5-fold for CPG41), suggesting that
CPG41 has a higher affinity for CXCR4 per se. Where
CXCR4 was abundant (CLL-CD134), inhibition of infec-
tion required significantly higher concentrations of
AMD3100 and even at 10 μg/ml antagonist, the degree of
inhibition never exceeded 80%. The data suggest that the
T271I and N342Y mutations do not alter the affinity of
the CXCR4 interaction significantly.
Sensitivity of glycosylation mutants to CXCR4 antagonistFigure 4
Sensitivity of glycosylation mutants to CXCR4 antagonist. Infection of MYA-1 and CLL-CD134 cells with HIV (FIV) pseudo-
types bearing WT, T271I or N342Y mutant GL8 and CPG41 Envs was quantified in the presence of increasing concentrations 
of CXCR4 antagonist AMD3100. Infection is expressed as luciferase activity (CPM) and percent infection relative to control 
(no antagonist). Each point represents the mean +/- SE of triplicate samples.
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We next asked whether the T271I or N342Y mutations
conferred CD134-independence upon the GL8 and
CPG41 Envs. Feline AH927 cells stably transduced with
vectors encoding feline CD134 or the CRD1 chimaera, or
the empty expression vector (pDONAI) only, were trans-
duced for a second time with vectors encoding feline
CXCR4 or human CXCR4, or expression vector (pBa-
bePuro only). Stable lines were selected that expressed
either low level endogenous feline CXCR4 (Fig. 5,
endog.)), high level feline CXCR4 (+feline), or high level
human CXCR4 (+human) in conjunction with either the
CRD1 chimaera or native CD134. The cells were then
infected with HIV(FIV) luciferase pseudotypes bearing the
GL8 and CPG41 Envs (wild type (WT), T271I, N342Y or
Δ2N double mutant) and infectivity assayed (Fig. 5). If the
T271I or N342Y mutations conferred CD134-independ-
ence, enhanced CXCR4 expression alone would be suffi-
cient to promote viral entry. Control cells expressing
endogenous CXCR4 were refractory to infection with all
viruses (Fig. 5A,B, "endog.") and ectopic expression of
CRD1 did not enhance infection (Fig. 5C,D, "endog."). In
contrast, ectopic expression of feCD134 (Fig. 5E,F,
"endog.") enhanced infection of the control with all
viruses (>10-fold) suggesting that sufficient endogenous
CXCR4 is present to facilitate viral entry in the presence of
native primary receptor. The addition of exogenous feline
or human CXCR4 alone did not enhance infection of the
control cells mediated by either the GL8 or CPG41 Envs
significantly, irrespective of whether WT, T271I, N342Y or
Δ2N (Fig. 5A,B, control). In contrast, the addition of exog-
enous CXCR4 in the presence of either the feline CD134
CRD1 chimera (Fig. 5C,D, CRD1), or native feline CD134
(Fig. 5E,F, CD134) revealed a significantly more marked
enhancement of infection with the T271I and Δ2N viruses
than with the WT or N342Y viruses. The data are consist-
ent with the T271I mutation removing the requirement of
the viral Env for determinants in CRD2 [30,63], and thus
improving its ability to utilise the CRD1 chimaera as an
effective viral receptor. Accordingly, the data suggest that
the N-linked glycosylation site ablated by the T271I muta-
tion either contributes to the binding site on FIV Env for
CD134, or constrains the conformation of Env such that
it may only interact with native feline CD134.
Binding of soluble Fc-SU fusion proteins to CD134-
expressing cells
Previous studies have demonstrated that soluble IgG-Fc-
FIV SU fusion proteins (Fc-SU) recapitulate the receptor
binding specificity of the parent virus [29,83-85]. We
therefore asked whether GL8 Fc-SU fusion proteins (pro-
teins that exist primarily as dimers) derived from the WT,
T271I or N342Y Envs (trimeric on the native virions)
would display the receptor binding properties of their
respective parent viruses. WT, T271I or N342Y GL8 Env
Fc-SUs bound to feline CD134 expressing MCC cells (Fig.
6A, row 1) but not to control MCC cells (Fig. 6A, row 4),
consistent with the usage of feline CD134 as a receptor on
MCC cells (Fig. 3B). However, a similar level of binding
was detected to cells expressing only CRD1 of feline
CD134 (Fig. 6A, row 2) suggesting that when the Envs
were expressed in soluble form as Fc-SU fusion proteins,
the requirement for determinants in CRD2 of CD134 for
receptor binding is lost. These data would suggest that the
specificity of receptor binding of the GL8 Env may be
dependent on intermolecular interactions in the tertiary
complex of the native trimeric Env on virions and accord-
ingly that the T271I mutation modulates this interaction.
As an additional control for binding specificity, we
assessed the binding of Fc-SU proteins to MCC cells
expressing human CD134. Neither the WT nor the T271I
and N342Y Envs support infection through human
CD134 ([30] and data not shown), however, significant
(albeit weak) binding of the WT, T271I and N342Y Fc-SU
proteins to human CD134-expressing MCC was detected
(Fig. 6A, row 3). It was notable that the MCC-derived cell
lines transduced with the feline CD134, CRD1 or human
CD134 expression vectors showed up-regulated expres-
sion of CXCR4 (48.5%, 63.1% and 87.6% respectively)
relative to vector-only control cells (14.8%) indicating
that the low level binding of the Fc-SU proteins to human
CD134 may not have been mediated by human CD134,
rather it could have reflected the marked up-regulation of
endogenous CXCR4 on these cells. Accordingly, when we
repeated the binding of WT Fc-SU to the four cell lines fol-
lowing pre-treatment of the cells with the CXCR4 antago-
nist AMD3100 and in the presence of anti-CXCR4
monoclonal antibody 44701 (Fig. 6B.), the low level of
background binding of Fc-SU to CXCR4 was reduced from
17.2% to 2.6%, consistent with a direct interaction
between the soluble SU and CXCR4, as has been noted
previously for both FIV and HIV [82,86]. Given that
CXCR4 expression alone does not confer susceptibility to
infection with WT GL8, and that WT GL8 does not infect
cells expressing CRD1 alone, these data suggest that the
Fc-SU fusion proteins are in a distinct conformation that
fails to mimic that found on native virions.
Effect of the T271I and N342Y mutations on sensitivity to 
virus neutralising antibody
The predicted N-linked glycosylation sites ablated by the
T271I and N342Y mutations are highly conserved among
field isolates of FIV and reinstated rapidly (as early as 1
month post-infection) following in vivo replication of
mutant virus [87]. These data suggest that the predicted N-
link glycosylation sites at N269 and N342 are critical for
maintaining the replicative capacity of the virus in vivo. It
is possible that glycosylation at these sites protects the
virus from virus neutralising antibody (VNA), thus the
sensitivity of HIV(FIV) pseudotypes bearing the wild typePage 9 of 16
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Effect of ectopic CXCR4 expression on infection with glycosylation mutantsFigure 5
Effect of ectopic CXCR4 expression on infection with glycosylation mutants. AH927 cells expressing low level endogenous 
CXCR4 (endog.) or enhanced levels of either feline CXCR4 (+feline) or human CXCR4 (+human), in conjunction with feline 
CD134 (feCD134), CRD1 of fCD134 in the context of hCD134 (CRD1), or vector-only control (Control), were infected with 
HIV(FIV) pseudotypes bearing the GL8 or CPG41 Envs. 72 hours post-infection luciferase activity was assayed. Each point rep-
resents the mean +/- SE of triplicate samples.
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Retrovirology 2008, 5:77 http://www.retrovirology.com/content/5/1/77GL8 Env or the T271I, N342Y and Δ2N mutants to sera
from 8 cats infected with GL8 (4 years post-infection) was
compared. Of the 8 sera evaluated, 5 sera (Q251, Q253,
Q254, Q255 and Q256) contained potent virus neutralis-
ing activity (>90% neutralisation at 1/100, Fig. 7) while
more modest neutralising activity was detected in sera
from Q252, Q257 and Q258 (Fig. 7). There was no con-
sistent difference in sensitivity to VNA between the WT
and the T271I, N342Y and Δ2N mutants, suggesting that
this region is not a major target for the humoral response
to wild type virus.
Discussion
The FL4 strain of FIV was derived by long-term in vitro cul-
ture of mixed peripheral blood lymphocytes from cats
infected with the Petaluma strain of FIV [68]. The IL-2-
independent cell line (FL4) derived from this mixed cell
culture stably produced FIV particles at a high level that,
following concentration and paraformaldehyde inactiva-
tion, provided the first effective vaccine against FIV infec-
tion [37], and the basis for the first commercial FIV
vaccine, Fel-O-Vax FIV. The FL4 Env would appear to be
both stable in its attachment to the viral particle during
purification, and highly immunogenic. Here we show that
the FL4 virus lacks predicted sites for N-linked glycosyla-
tion that are highly conserved in the majority of field
strains of FIV. The location of these mutations, T271I and
N342Y, is strikingly similar to previously described N-
linked glycosylation sites in the Env of SIV and HIV that
may contribute to enhanced immunogenicity of Env-
based immunogens and an altered receptor usage in vitro
[12,25,26,88]. Given the conservation of these sites in
field strains, we predicted that one or both of these muta-
tions may contribute to the process of cell culture adapta-
tion which previous studies have shown to result in an
increase in charge of the FIV Env V3-loop homologue and
utilisation of CXCR4 alone as a viral receptor (CD134-
independent infection) [27,33,34,89,90]. When the
T271I and N342Y mutations were introduced into two
primary field strains of FIV (GL8 and CPG41), the T271I
Binding of FIV Fc-SU fusion proteins to CD134-expressing cellsF gure 6
Binding of FIV Fc-SU fusion proteins to CD134-expressing cells. (A) MCC cells stably-transduced with retroviral vectors 
encoding full-length fCD134 (Feline), CRD1 of fCD134 in the context of hCD134 (CRD1), human CD134 (Human) or vector 
only control (CON) were incubated with Fc-SU fusion proteins derived from GL8 WT or glycosylation site mutants T271I and 
N342Y and bound protein detected using PE-anti-human IgG Fc by flow cytometry. CXCR4 and CD134 expression were 
assayed using anti-CXCR4 (44701) and CD134 (7D6) respectively followed by PE-anti-mouse IgG. (B) Inhibition of residual 
WT GL8 Fc-SU binding to human CD134 expressing cells by anti-CXCR4. Cells were pre-incubated with AMD3100 and 44701 
prior to binding of WT Fc-SU and detection of bound protein by flow cytometry using PE-anti-human IgG Fc. Histograms show 
10,000 events and are representative of at least two independent experiments.
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Retrovirology 2008, 5:77 http://www.retrovirology.com/content/5/1/77mutation was shown to have a significant modulatory
effect on the way the virus interacts with CD134. The GL8
and CPG41 strains of FIV recognise a complex determi-
nant on CD134 that is dependent on residues in both
CRD1 and CRD2 of the molecule, while strains such as
PPR and B2542 are able to infect cells using a minimal
determinant in CRD1 alone, suggesting a less complex
interaction with CD134 [30,63,84]. That the removal of a
single site for N-linked glycosylation (T271I) is sufficient
to switch both GL8 and CPG41 from a complex to a min-
imal interaction would suggest that the N-linked glyco-
sylation site ablated by the T271I mutation either forms a
component of the receptor binding face of FIV Env, or
contributes to the tertiary/quaternary structure of the Env
trimer such that the receptor binding face of Env is pre-
sented to the viral receptor in the correct configuration.
Sensitivity of GL8 WT and T271, N342Y and Δ2N mutants to virus neutralising antibodyFigure 7
Sensitivity of GL8 WT and T271, N342Y and Δ2N mutants to virus neutralising antibody. HIV (FIV) pseudotypes bearing the 
WT, T271, N342Y or Δ2N Envs were incubated with 1/100, 1/1000 or 1/10,000 dilutions of plasma from 8 GL8-infected cats 
(Q251-258), or a no plasma negative control (neg), and plated onto CLL-CD134 cells. Luciferase activity was assayed at 72 hrs 
post-infection. (A) Luciferase activity (counts per minute), each point represents the mean of three replicates +/- SE, (B) Per-
cent neutralisation relative to no plasma control.
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Retrovirology 2008, 5:77 http://www.retrovirology.com/content/5/1/77These data are reminiscent of studies with HIV-1 ADA
where removal of an N-linked glycosylation site at the
base of the V1V2 stem (N197) facilitated CD4-independ-
ent infection of canine cells through CCR5 [12], an effect
that was postulated to be mediated by repositioning of the
V1V2 loops and exposure of the CCR5 binding site [12].
An N197D mutation in Env improved CXCR4 utilisation
by HIV ADA-1 following co-receptor switching from
CCR5 to CXCR4 [91]. The mutations in V3 that conferred
CXCR4 usage upon the virus were in themselves deleteri-
ous; it has been suggested that by altering the flexibility of
the V1V2 loop, the N197D mutation compensated for the
mutations in V3 that facilitated switching from CCR5 to
CXCR4 usage [91]. Mutation of glycosylation sites adja-
cent to the V1V2 loops of HIV-1 DH12, a dual-tropic
strain of HIV, either reduced or abolished completely cell-
cell fusion mediated by both CXCR4 and CCR5 [92], this
effect appeared to result, in part, from a marked reduction
in CD4 binding by the mutated Env [92].
Several studies have demonstrated that the V1V2 region of
HIV Env plays an important role in viral cell tropism and
receptor binding [52-57]. For example, in early studies,
mutations in the V1/V2 loop of HIV-1 HXBc2 were
observed to reduce both CD4-binding capacity and syncy-
tium formation [56] while subsequently, determinants in
V1/V2 were found to contribute to CCR3 usage in that
substitution of the V1/V2 loop of the dual-tropic (R3/R5)
strain ADA into the R5 strain BaL rendered the Env dual-
tropic [93]. Solution of the crystal structure of the deglyc-
osylated gp120 core in complex with CD4 and antibody
17b indicated that the stem of the V1 and V2 loops of HIV
Env contributes to the "bridging sheet", a four-stranded
anti-parallel β-sheet that mediates chemokine receptor
binding [7,94]. Binding of CD4 is thought to reposition
the V1V2 loop stem (the V1V2 loop stem itself contacts
CD4 [7]), facilitating the formation of the bridging sheet
structure and subsequently permitting chemokine recep-
tor binding. Thus modifications to the structure of the
V1V2 loop may mimic CD4-binding and facilitate chem-
okine receptor binding. The T271I mutation in FIV Env
may have a similar function; either by altering directly a
contact point with CD134 or by facilitating CD134-inde-
pendent infection. In this study, we found that the T271I
mutation did not confer CD134-independent infection,
rather it modulated usage of CD134 by the primary FIV
Envs, reducing the requirement for residues in CRD2 of
CD134 for viral entry and syncytium formation. A similar
mode of interaction with CD134 has been described for
the PPR and B2542 strains of virus, both of which are able
to readily infect cells using CRD1 of CD134 alone [30,63].
Both the PPR [95] and B2542 [96] are capable of inducing
immunological and neurological abnormalities in vivo
that are consistent with immunodeficiency-causing lenti-
viruses, thus the ability of viruses to infect cells using
CRD1 of CD134 alone is not in itself, debilitating to viral
replication. It is possible that the nature of the interaction
between the viral Env and CD134 changes with disease
progression, in early infection viruses employ a high affin-
ity complex interaction involving determinants in both
CRD1 and CRD2 and in doing so may protect the virus
from neutralising antibody or endogenous CD134-ligand
(infection with PPR and B2542 is sensitive to modulation
by CD134L [28]). As disease progresses, the Env-CD134
interaction may become less stringent, allowing the virus
to expand more readily into CD134-negative cellular
compartments through direct interactions with CXCR4. If
N-linked glycosylation at N-269 contributes to the com-
plexity of the Env-CD134 interaction in vivo, we would
predict that late isolates of FIV would be more likely to
harbour viral variants bearing mutations such as the
T271I observed in FL4. Conversely, in early infection, viral
variants bearing T271 would be suppressed. This hypoth-
esis has been tested to some extent in a study in which cats
were infected with the FL4 strain and virus re-isolated
three years post infection [87]. Sequence analysis revealed
an I271T reversion in 2 out of 3 cats and Y342N mutation
in 3 of 3 cats [87], suggesting a strong selective pressure in
favour of either reinstating the N-linked glycosylation
sites following infection or suppressing the replication of
T271I and Y342N bearing variants in vivo.
Neither the T271 nor the N342Y mutations affected the
sensitivity of GL8 to neutralisation by sera from cats
infected with the biological isolate of GL8, suggesting that
this region may not be a primary target for neutralising
antibodies in vivo. The N-linked glycosylation sites
affected by the T271I and N342Y mutations in FIV lie in a
predicted loop domain of FIV Env [76] that is analogous
to the V1/V2 loop of HIV in schematic structural models
[75]. V1 and V2 of FIV Env were originally assigned to
hypervariable regions located in the leader and signal
sequence regions of FIV Env [76], however, to facilitate
ready comparisons between FIV and HIV we refer to the
region between amino acids 248 and 354 as the V1/V2
homologue. The conservation of this region amongst viral
strains is consistent with the region not being under a
strong selective pressure from the host immune system.
However as the Fel-O-Vax FIV vaccine is derived from FL4
virus bearing the T271I and N342Y mutations, it is possi-
ble that deglycosylation of this region in the vaccine strain
may render the region immunogenic for vaccinates and
contribute to protection from challenge.
In conclusion, we have shown that a single glycosylation
site ablated in V1V2-loop homologue of FIV modulates
the Env-CD134 interaction. As this glycosylation site is
ablated in the FL4 vaccine strain, future studies should
address whether antibodies induced by vaccination with
immunogens bearing this mutation target this region ofPage 13 of 16
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Retrovirology 2008, 5:77 http://www.retrovirology.com/content/5/1/77the Env and whether selective deglycosylation of this
region may offer a strategy for the rationale design of FIV
vaccines.
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